36 results
SC 14D9/A
EX-99
PNT
POINT Biopharma Global Inc.
18 Dec 23
Tender offer solicitation (amended)
8:14am
Black or African American.
“The success of 177Lu-PNT2002 in this trial demonstrates the value of treating patients with radioligand therapy
8-K
PNT
POINT Biopharma Global Inc.
13 Jun 23
Departure of Directors or Certain Officers
4:45pm
an approximate value of $412,500, calculated by dividing such amount by the Black-Scholes Value as of the date of grant. On a go-forward basis, Dr
ARS
bd0g3c4ec5 7joepyd
1 May 23
Annual report to shareholders
1:52pm
8-K
EX-99.2
4z2vieo
12 Sep 22
POINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial in mCRPC at ESMO Congress 2022
7:54am
424B3
wprtk6d3x
13 May 22
Prospectus supplement
8:18am
DEF 14A
a418b353diu
28 Apr 22
Definitive proxy
8:36am
424B3
sic4d543efebhry1t2i
31 Mar 22
Prospectus supplement
11:42am
POS AM
3p1 03flz
25 Mar 22
Prospectus update (post-effective amendment)
8:41am
424B3
quhe2p 4qzx9f3f
12 Nov 21
Prospectus supplement
8:41am
424B3
o9dccvj05umw
13 Aug 21
Prospectus supplement
5:25pm